{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-119976","form_type":"8-K","ticker":"RIGL","cik":"0001034842","company_name":"RIGEL PHARMACEUTICALS INC","filed_at":"2025-12-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.602577+00:00","generated_at":"2026-05-16T13:36:59.479912+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Rigel reports R289 Phase 1b data: 33% RBC-TI in evaluable lower-risk MDS patients","bullets":["33 patients enrolled (median age 75, median 3 prior therapies); 61% high transfusion burden at baseline.","6/18 evaluable transfusion-dependent patients at doses ≥500 mg QD achieved RBC-TI >8 weeks; median duration 22.9 weeks.","R289 generally well tolerated; most common Grade 3/4 AEs: anemia (18%), neutropenia and pneumonia (each 15%).","Dose expansion phase ongoing; RP2D selection expected H2 2026.","R289 granted FDA Orphan Drug and Fast Track designations for MDS."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-119976","json":"https://secwatch.observer/filing/0001104659-25-119976.json","markdown":"https://secwatch.observer/filing/0001104659-25-119976.md","text":"https://secwatch.observer/filing/0001104659-25-119976.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1034842/000110465925119976/0001104659-25-119976-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1034842/000110465925119976/tm2533140d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:36:59.479912+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}